Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CA-170 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| CA-170 | EXPERIMENTAL | Taken orally in a once or twice daily schedule. |
| Name | Type | Description |
|---|---|---|
| CA-170 | DRUG | Dose escalation stage (Phase 1a) accelerated titration and standard 3+3 dose escalation in patients with advanced solid tumor or lymphoma. Dose expansion stage (Phase 1b) in patients with tumors that are shown to be responsive to anti-PD-1 or anti-PD-L1 checkpoint inhibitors and/or in tumor types known to express PD-L1 or VISTA, including but not limited to: mesothelioma, melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, triple negative breast cancer, head and neck cancer, colorectal cancer, gastric cancer, bladder cancer, and ovarian cancer. |
Inclusion Criteria: 1. Males and females ≥ 18 years of age; 2. Life expectancy of at least 3 months; 3. ECOG PS ≤ 1; 4. Acceptable bone marrow and organ function at screening; 5. Ability to swallow and retain oral medications; 6. Negative serum pregnancy test in women of childbearing potential; 7. ...
CA-170 is an investigational oral small molecule developed by Curis, Inc. as an immune checkpoint antagonist. It was studied in patients with advanced solid tumors or lymphomas. It is not a marketed product and remains in clinical development.
CA-170 was studied for the treatment of advanced solid tumors or lymphomas. Its only recorded clinical trial enrolled adults with those advanced cancers. It is investigational and has not been established as a treatment for any indication.
CA-170 targets PD-L1, and it is described as an oral PD-L1, PD-L2 and VISTA checkpoint antagonist. It is a small molecule in the immune checkpoint class, designed to act on these checkpoint proteins rather than on a tumor's driving mutation.
CA-170 is being developed by Curis, Inc., which trades on the Nasdaq under the ticker CRIS. Curis is the sponsor associated with the clinical program for this oral checkpoint antagonist.
CA-170 is in Phase 1 development. Its single recorded trial, NCT02812875, was a Phase 1 study that has been completed. The drug is investigational and has not been approved by the FDA for any indication.
CA-170 has been evaluated in one clinical trial, NCT02812875, titled A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas. That Phase 1 trial is completed, enrolled 71 patients, and ran in the United States, South Korea, Spain and the United Kingdom.